Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Google Secures Pentagon AI Deal for Classified Projects 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
MALVERN, Pa., May 01, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biotechnology company, will release its first quarter financial results before the market opens on May 9, 2017.
Management will conduct a conference call at 4:30 PM ET that day to discuss the Company’s financial results and provide a general business update. The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Company’s website for 30 days following the call.
To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 5101760 prior to the start of the call.
About Aclaris
Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
